Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Moodys
AstraZeneca
Colorcon
McKinsey
Boehringer Ingelheim

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Patent: 9,642,872

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,642,872
Title:Treatment of B-cell lymphoma with microRNA
Abstract: The invention relates to microRNA-34a and related microRNAs for use in the treatment of B-cell lymphoma. Likewise it relates to microRNA-34a for use in the preparation of a medicament for the treatment of B-cell lymphoma, and for a method of treatment of B-cell lymphoma comprising administering microRNA-34a. These claims are based on the observation that microRNA-34a shows strong anti-proliferative effects when overexpressed in diffuse large B-cell lymphoma (gDLBCL) cell lines, or when delivered intratumorally or systemically in xenograft models of DLBCL.
Inventor(s): Craig; Vanessa (Zurich, CH), Mueller; Anne (Dubendorf, CH)
Assignee: UNIVERSITY OF ZURICH (Zurich, CH)
Application Number:14/565,049
Patent Claims:see list of patent claims

Details for Patent 9,642,872

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial UNIVERSITY OF ZURICH (Zurich, CH) 2030-09-30 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial UNIVERSITY OF ZURICH (Zurich, CH) 2030-09-30 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial UNIVERSITY OF ZURICH (Zurich, CH) 2030-09-30 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial UNIVERSITY OF ZURICH (Zurich, CH) 2030-09-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Johnson and Johnson
Dow
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.